BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Borren NZ, Plichta D, Joshi AD, Bonilla G, Sadreyev R, Vlamakis H, Xavier RJ, Ananthakrishnan AN. Multi-"-Omics" Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse. Inflamm Bowel Dis 2020;26:1524-32. [PMID: 32766830 DOI: 10.1093/ibd/izaa183] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Li M, Yang L, Mu C, Sun Y, Gu Y, Chen D, Liu T, Cao H. Gut Microbial Metabolome in Inflammatory Bowel Disease: from Association to Therapeutic Perspectives. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.03.038] [Reference Citation Analysis]
2 Aldars-García L, Marin AC, Chaparro M, Gisbert JP. The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review. Int J Mol Sci 2021;22:3076. [PMID: 33802883 DOI: 10.3390/ijms22063076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Aldars-García L, Chaparro M, Gisbert JP. Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease. Microorganisms 2021;9:977. [PMID: 33946482 DOI: 10.3390/microorganisms9050977] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
4 Shah RS, Click BH. Medical therapies for postoperative Crohn's disease. Therap Adv Gastroenterol 2021;14:1756284821993581. [PMID: 33643440 DOI: 10.1177/1756284821993581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Santoru ML, Piras C, Murgia F, Leoni VP, Spada M, Murgia A, Liggi S, Lai MA, Usai P, Caboni P, Manzin A, Atzori L. Metabolic Alteration in Plasma and Biopsies From Patients With IBD. Inflamm Bowel Dis 2021;27:1335-45. [PMID: 33512485 DOI: 10.1093/ibd/izab012] [Reference Citation Analysis]
6 Giachero F, Jenke A, Zilbauer M. Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine. Expert Rev Clin Immunol 2021;17:871-81. [PMID: 34142929 DOI: 10.1080/1744666X.2021.1945442] [Reference Citation Analysis]
7 Bjerrum JT, Wang YL, Seidelin JB, Nielsen OH. IBD metabonomics predicts phenotype, disease course, and treatment response. EBioMedicine 2021;71:103551. [PMID: 34419930 DOI: 10.1016/j.ebiom.2021.103551] [Reference Citation Analysis]
8 Aldars-García L, Gisbert JP, Chaparro M. Metabolomics Insights into Inflammatory Bowel Disease: A Comprehensive Review. Pharmaceuticals (Basel) 2021;14:1190. [PMID: 34832973 DOI: 10.3390/ph14111190] [Reference Citation Analysis]
9 Noor NM, Sousa P, Paul S, Roblin X. Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD. Inflamm Bowel Dis 2021:izab228. [PMID: 34480558 DOI: 10.1093/ibd/izab228] [Reference Citation Analysis]